SCHEMBL8064171

SCHEMBL8064171

O=C(C=Cc1cccc(F)c1)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.59
▸ EGFR P00533 3/20 0.58
▸ TRPM2 O94759 2/20 0.57
▸ TRPA1 O75762 2/20 0.57
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ MMP1 P03956 7/20 0.53
▸ MMP2 P08253 7/20 0.53
▸ MMP9 P14780 7/20 0.53
▸ MAOB P27338 2/20 0.50
▸ MAOA P21397 1/20 0.50
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8064168 1.00 GAA (0.59) GAAEGFRTRPM2TRPA1NPC1
SCHEMBL8060347 0.91 GAA (0.61) GAAEGFRTRPM2TRPA1NPC1
SCHEMBL8060344 0.91 GAA (0.61) GAAEGFRTRPM2TRPA1NPC1
SCHEMBL8059594 0.90 MEN1 (0.67) EGFRTRPM2TRPA1NPC1RAB9A
SCHEMBL8059593 0.90 MEN1 (0.67) EGFRTRPM2TRPA1NPC1RAB9A
SCHEMBL8060454 0.87 EGFR (0.75) GAAEGFRTRPM2TRPA1NPC1
SCHEMBL8060457 0.87 EGFR (0.75) GAAEGFRTRPM2TRPA1NPC1
SCHEMBL8065974 0.86 TRPA1 (0.68) EGFRTRPM2TRPA1NPC1RAB9A
SCHEMBL8065971 0.86 TRPA1 (0.68) EGFRTRPM2TRPA1NPC1RAB9A
SCHEMBL417073 0.86 EGFR (0.62) EGFRTRPM2TRPA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6127392-A A MUSCLE RELAXANT FOR TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION; INOTROPIC AGENT AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-03 — — US disclosed
US-6046239-A USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION SUCH AS URINARY INCONTINENCE, ASTHMA, ANGINA, PREMATURE LABOR, CONGESTIVE HEART FAILURE AMERICAN HOME PRODUCTS CORPORATION (US) 2000-04-04 — — US disclosed
Send feedback